RETATRUTIDE 15mg

Retatrutide is a novel triple agonist peptide studied for human-relevant research on metabolic regulation, appetite control, and metabolic regulation. It combines GLP-1, GIP, and glucagon receptor activity to provide a comprehensive approach for investigating glycemic control, energy balance, and cardiometabolic health.

Key Features

• cGMP manufactured in an FDA-registered facility
• ≥98% purity confirmed by HPLC analysis
• Batch-specific Certificates of Analysis (COAs) included

Human-Relevant Research Applications

Glycemic control and insulin sensitivity
Improves glycemic markers (HbA1c, fasting glucose) in type 2 diabetes and metabolic syndrome contexts.
https://pubmed.ncbi.nlm.nih.gov/40291085/

Metabolic regulation and appetite regulation
Leads to significant metabolic regulation and appetite signalling modulation.
https://pubmed.ncbi.nlm.nih.gov/40916752/

Cardiometabolic research
Associated with better metabolic outcomes including weight, glucose, BMI, and blood pressure in clinical trials.
https://pubmed.ncbi.nlm.nih.gov/39318607/

Mechanism Summary

• Dual and triple receptor activity (GLP-1, GIP, glucagon) enhances glucose regulation and metabolic outcomes.
• Modulates satiety and energy homeostasis, supporting human-relevant research in obesity and diabetes.
• Enables studies on cardiometabolic health, metabolic regulation, and insulin sensitivity.

Frequently Research Questions

How does Retatrutide differ from GLP-1 analogues?
Retatrutide's triple receptor activity offers broader metabolic and metabolic regulation effects than GLP-1 alone.

Is it suitable for long-term human-relevant studies?
Yes. It allows chronic investigation of insulin sensitivity, weight control, and cardiometabolic outcomes.

Does it affect cardiovascular markers?
Studies show beneficial effects on lipid profiles, blood pressure, and other cardiometabolic indicators.

Scientific References

Frias et al. (2023) — Retatrutide triple agonist effects on glycemic control. Retatrutide significantly lowers HbA1c and improves glucose control in adults with type 2 diabetes.
https://pubmed.ncbi.nlm.nih.gov/37385280/

Jastreboff et al. (2023) — Triple agonist peptides and appetite/weight regulation. Retatrutide produces substantial concentration-dependent metabolic regulation and appetite signalling modulation in adults with obesity.
https://pubmed.ncbi.nlm.nih.gov/40916752/